Inicio/ZTS

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze ZTS in workspace
ZTSNYSE/health care

Zoetis Inc.

$75.39Down-0.17 (-0.22%)
Research reviewed: 12 jul 2026, 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

Zoetis Inc. operates in Pharmaceuticals within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

시가
75.90
고가
76.50
저가
74.53
시가총액
316.06억
PER
12.36
52주 최고가
--
배당
2.810%
분기 배당금
--

3-month price context

El gráfico muestra la tendencia reciente de 3 meses para entender la estructura de corto plazo antes de abrir el workspace completo.

Investment thesis

Base case
Pet owners' focus on longevity and quality of life can sustain medicines, vaccines and diagnostics demand. The base case remains conditional on product safety staying manageable.
Bull case
Pet owners' focus on longevity and quality of life can sustain medicines, vaccines and diagnostics demand. Librela and Solensia can expand treatment of chronic pain in dogs and cats as veterinarian familiarity grows. New vaccines, diagnostics and monoclonal antibodies can extend a differentiated portfolio.
Bear case
Adverse-event concerns or label changes could slow adoption of important companion-animal products. Clinic staffing constraints and affordability pressure can limit visits, diagnoses and treatment starts. Disease outbreaks, commodity economics and regulation can cause abrupt changes in producer demand.
Thesis invalidation
Reassess the thesis if adverse-event concerns or label changes could slow adoption of important companion-animal products.

Key catalysts

  • Companion-animal spending

    Pet owners' focus on longevity and quality of life can sustain medicines, vaccines and diagnostics demand.

  • Osteoarthritis franchise

    Librela and Solensia can expand treatment of chronic pain in dogs and cats as veterinarian familiarity grows.

  • Animal-health innovation

    New vaccines, diagnostics and monoclonal antibodies can extend a differentiated portfolio.

Principal risks

  • Product safety

    Adverse-event concerns or label changes could slow adoption of important companion-animal products.

  • Veterinary capacity

    Clinic staffing constraints and affordability pressure can limit visits, diagnoses and treatment starts.

  • Livestock volatility

    Disease outbreaks, commodity economics and regulation can cause abrupt changes in producer demand.

Latest earnings research

Q1 2026

Zoetis's first-quarter 2026 update reflected continued companion-animal demand, growth-product contributions in pain, parasiticides and dermatology and resilient livestock operations across geographies.

Valuation interpretation

  • A defensive-growth premium depends on companion-animal innovation remaining durable after launch and safety scrutiny.
  • Portfolio breadth across species and geographies offsets some risk but does not eliminate veterinary-capacity and livestock cycles.

Peer research

JNJLLYMRK

Recent news

24/7 Wall St. · 3일 전

A Dividend Portfolio That Pays For Your Pets

StockStory · 4일 전

2 Value Stocks with Promising Prospects and 1 That Underwhelm

Zacks · 5일 전

ZTS Wins European Commission Approval for New Poultry Disease Vaccine

Bloomberg · 8일 전

Deadly Screwworm’s Leap Into the US Mystifies Health Experts

Stocktwits · 11일 전

Michael Burry Just ‘Shorted Micron’ — Why He Says AI-Fueled Rally Has Pushed MU Into Bubble Territory

StockStory · 12일 전

Branded Pharmaceuticals Stocks Q1 Teardown: Zoetis (NYSE:ZTS) Vs The Rest

Data and research sources

Research updated: 12 jul 2026, 00:00 UTC
3 verified sources
Zoetis Reports First Quarter 2026 ResultsZoetis Inc. · earningsVerified

Fetched: 12/7/2026, 0:00:00 UTC

Published: 5/5/2026, 0:00:00

Open original source
Zoetis Inc. Investor RelationsZoetis Inc. · companyVerified

Fetched: 12/7/2026, 0:00:00 UTC

Open original source
Zoetis SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 12/7/2026, 0:00:00 UTC

Published: 5/5/2026, 0:00:00

Open original source

Continue in the research workspace

Keep ZTS in context, run a multi-agent analysis, and monitor thesis changes.

Analyze ZTS free

Explora todo el sistema de análisis

Cada etapa cumple una función concreta y deja un resultado auditable.

Metodología de análisisLeer informes de mercadoExplorar acciones

Continue researching this stock

Analista de Mercado

Analista de Mercado se especializa en la etapa de Observar dentro de Investigación central y ordena el contexto para los siguientes roles.

Analista Fundamental

Analista Fundamental se especializa en la etapa de Observar dentro de Investigación central y ordena el contexto para los siguientes roles.

Analista de Noticias

Analista de Noticias se especializa en la etapa de Observar dentro de Investigación central y ordena el contexto para los siguientes roles.

Gerente de Riesgo

Gerente de Riesgo se especializa en la etapa de Monitorizar dentro de Riesgo y monitoreo y ordena el contexto para los siguientes roles.